Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Medicinova Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MNOV
Nasdaq
8731
https://medicinova.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Medicinova Inc
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
- Apr 2nd, 2024 11:00 pm
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
- Mar 26th, 2024 11:00 pm
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
- Mar 20th, 2024 11:00 pm
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
- Mar 20th, 2024 2:58 pm
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
- Mar 12th, 2024 10:30 am
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
- Feb 29th, 2024 10:34 am
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
- Jan 17th, 2024 11:00 am
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
- Dec 21st, 2023 11:00 pm
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
- Dec 6th, 2023 11:00 pm
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
- Nov 27th, 2023 10:27 am
The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable
- Nov 22nd, 2023 10:10 am
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
- Nov 19th, 2023 11:00 pm
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
- Oct 27th, 2023 5:00 am
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
- Oct 12th, 2023 2:20 pm
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
- Oct 10th, 2023 11:00 pm
MediciNova Receives Gene Therapy Milestone Payment
- Oct 4th, 2023 11:00 pm
MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…
- Sep 29th, 2023 1:11 pm
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
- Sep 27th, 2023 11:00 pm
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…
- Aug 21st, 2023 12:00 pm
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
- Aug 17th, 2023 11:00 pm
Scroll